|
Continua a leggere Owkin Unveils AI - Driven Oncology and Immunology Pipeline, In - Licenses Best - in - Class Asset OKN4395 Business Wire Business Wire - 23 Maggio 2024 Owkin has unveiled its ...
01Net
-
23-5-2024
|
|
|
|
Continua a leggere Owkin Unveils AI - Driven Oncology and Immunology Pipeline, In - Licenses Best - in - Class Asset OKN4395 Business Wire Business Wire - 23 Maggio 2024 Owkin has unveiled its ...
01Net
-
23-5-2024
|
|
|
|
Operating throughout Latin America with fully owned subsidiaries, we hold leading positions in CNS, Immunology, Dermatology, Gastroenterology, Oncology, and Rare Disease biopharmaceuticals. Our ...
Adnkronos
-
22-5-2024
|
|
|
|
Topics covered include: the prevention and treatment of obesity, diabetes, metabolic disorders, and other noncommunicable diseases (NCDs) alongside research on allergies, immunology, the microbiome, ...
01Net
-
16-5-2024
|
|
|
|
... Flaminia Catteruccia , Director del PhD Program in Biological Sciences in Public Health, Immunology and Infectious Diseases presso la T. H. Chan School of Public Health di Harvard. Nella seconda ...
SardegnaLive
-
13-5-2024
|
|
|
|
... Flaminia Catteruccia , Director del PhD Program in Biological Sciences in Public Health, Immunology and Infectious Diseases presso la T. H. Chan School of Public Health di Harvard. Nella seconda ...
Oggi Treviso
-
10-5-2024
|
|
|
|
... Flaminia Catteruccia, Director del PhD Program in Biological Sciences in Public Health, Immunology and Infectious Diseases presso la T. H. Chan School of Public Health di Harvard. Nella seconda ...
Web Magazine 24
-
3-5-2024
|
|
|
|
Lo studio, pubblicato dal prestigioso Journalist of Allergy And Clinical Immunology Global, indica come responsabili principali delle allergie tra gli junior il latte, responsabile del 55% dei casi, ...
La Stampa
-
2-5-2024
|
|
|
|
È quanto evidenzia, su Nature Immunology , un team dell'Imperial College di Londra, coordinato da Peter Openshaw. L'analisi è stata condotta su oltre 650 persone ricoverate con Covid - 19 grave, di ...
QuotidianoSanità.it
-
30-4-2024
|
|
|
|
Massimo Fantini, Director of Research and Development with a strong background in Cancer Immunotherapy, Immunology and Cancer Research.
FarodiRoma
-
27-4-2024
|
|
|
|
|
|
